Inês de Sá

Inês specialises in intellectual property and data privacy, advising companies and brands on AI, digital assets, copyright, GDPR and Health Data compliance and consumer protection.

She provides day-to-day legal advice to distribution and retail companies, combining expertise in intellectual property, consumer protection, data protection and commercial contracts to support business operations and regulatory compliance.

Her practice also focuses on the procurement and implementation of AI solutions, advising clients on contract negotiation, AI regulation compliance, data protection and intellectual property considerations. She regularly assists businesses in navigating the complex regulatory landscape of AI systems, including GDPR requirements, the EU AI Act and sector-specific obligations.

Inês acts as external counsel to Data Protection Officers across multiple organisations, providing strategic guidance on privacy impact assessments, data breach management, cross-border data transfers and regulatory investigations.

She has extensive experience advising on business-to-consumer privacy matters, including consent management, marketing compliance and consumer rights.

She has also contributed to public sector data governance projects, advising on regulatory frameworks for centralised data platforms, lawful bases for processing and interoperability requirements.

• She advised Generis Farmacêutica, S.A. in a high-stakes patent infringement action brought before the Lisbon Intellectual Property Court by Recordati. The dispute concerns the generic medicine Silodosin (reference product: Urolec) and European Patent EP 1806 136. The matter is strategically significant due to its impact on market access for generics and the broader implications for pharmaceutical patent enforcement in Portugal.
• She represented Doc Generici in two parallel patent infringement actions brought before the Lisbon Intellectual Property Court by Bristol-Myers Squibb and Swords Laboratories. The disputes concerned both the product and formulation patents protecting the active pharmaceutical ingredient Apixaban. The matter was strategically significant due to the commercial relevance of Apixaban and its role in anticoagulant therapies.
• She advised Aurobindo Pharma Group on the implementation of generic protection strategies in Portugal, aligned with the group’s global market entry objectives. Our role includes strategic and technical-legal guidance on regulatory and IP matters, particularly in the context of patent disputes involving reference medicines. The matter is of high strategic and economic relevance, given the therapeutic importance and market value of the active substances involved.

• Faculdade de Direito da Universidade de Lisboa, 1997
• Pós-graduação em Direito da Sociedade da Informação Faculdade de Direito da Universidade de Lisboa, 2002